



## Targeted Radioligand Therapy and Immunotherapy for Cancer Treatment

Guest Editors:

**Dr. Jinda Fan**

Departments of Radiology,  
Chemistry, Institute of  
Quantitative Health Science and  
Engineering, Michigan State  
University, East Lansing, MI  
48824, USA

**Dr. Carolina de Aguiar Ferreira**

Departments of Radiology,  
Pharmacology and Toxicology,  
Institute of Quantitative Health  
Science and Engineering,  
Michigan State University, East  
Lansing, MI 48824, USA

Deadline for manuscript  
submissions:

**31 August 2024**

### Message from the Guest Editors

Targeted radioligand therapy and immunotherapy have emerged as transformative approaches within the oncological landscape, offering new avenues for personalized and effective cancer treatment. The combination of these modalities holds significant promise in enhancing treatment outcomes, overcoming resistance mechanisms and improving patient survival rates.

We welcome original research articles, reviews, clinical studies, case reports and perspectives addressing various aspects of targeted radioligand therapy and immunotherapy in cancer treatment, including but not limited to, the following:

1. Mechanisms of action and biological interactions between targeted radioligand therapy and immunotherapy;
2. Preclinical and clinical efficacy of combined targeted radioligand therapy and immunotherapy in different cancer types;
3. Radiobiology and immunobiology of the tumor microenvironment in the context of combined therapy;
4. Novel strategies for optimizing the combination of targeted radioligand therapy and immunotherapy;
5. Novel biomarkers and prediction of response to combined therapy;
6. Technological advancements and innovations in targeted radioligand therapy and immunotherapy delivery





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Maurizio Battino

Department of  
Odontostomatologic and  
Specialized Clinical Sciences,  
Sez-Biochimica, Faculty of  
Medicine, Università Politecnica  
delle Marche, Via Ranieri 65,  
60100 Ancona, Italy

## Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Biochemistry & Molecular Biology*) / CiteScore - Q1 (*Inorganic Chemistry*)

## Contact Us

*International Journal of Molecular  
Sciences* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/ijms  
ijms@mdpi.com  
X@IJMS\_MDPI